Brochure | October 30, 2023

Psychedelics: Drug Development Capabilities

GettyImages-1306664598 lab research

Psychedelics are emerging as a powerful tool for treating a number of mental health conditions, such as depression, post-traumatic stress disorder, substance use disorders, and others. Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and an apparent expansion of consciousness.

While there is growing interest in tapping into the therapeutic potential of psychedelics, only a handful of companies in the US hold DEA licenses for manufacturing Schedule I of II drug products. Adhering to the strict guidelines for handling and manufacturing Schedule I and II products requires regulatory expertise and years of experience in the space.

Societal has completed key regulatory requirements for moving forward with this work and is now positioned to support customers with the manufacture of high-quality cGMP clinical supplies. Learn how harnessing a CDMO’s extensive knowledge and skills in dealing with controlled substances can help you advance your innovative psychedelic therapeutic safely and efficiently.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online